Skip to main content

Table 1 Baseline characteristics

From: Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

 Evolocumab
(n = 16)
Placebo
(n = 14)
P value
Age, years58.6 (7.6)61.4 (7.5)0.317
Gender, n male (%)7 (44)7 (50)0.732
BMI, kg/m225.5 (3.4)26.6 (4.0)0.493
Smoking, n active (%)2 (13)0 (0)0.171
SBP, mmHg137 (16)139 (12)0.574
DBP, mmHg82 (8)86 (8)0.317
CVD, n (%)3 (19)1 (7)0.351
Medication use, n (%)
 Statins11 (69)7 (50)0.296
 Ezetimibe3 (19)4 (29)0.526
 Total cholesterol, mmol/La5.46 (0.92)5.62 (0.76)0.603
 LDL-cholesterol, mmol/La3.36 (0.70)3.68 (0.68)0.197
 HDL-cholesterol, mmol/La1.46 (0.43)1.35 (0.37)0.519
 Triglycerides, mmol/Lb1.38 [1.19–1.54]1.28 [0.91–1.63]0.533
 ApoB, g/l1.00 [0.93–1.15]1.07 [0.92–1.17]0.633
 Lipoprotein(a), nmol/Lc254 [182–297]154 [138–300]0.430
 hs-CRP, g/l0.75 [0.58–1.58]1.05[0.53–1.92]0.546
  1. Data are mean (SD), median [interquartile range], or n (%). ApoB, apolipoprotein B; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); SBP, systolic blood pressure
  2. aTo convert to mg/dL, multiply by 38.7, b To convert to mg/dL, multiply by 88.6, c To convert to mg/dL, divide by 2.5
  3. Wilcoxon rank-sum test was used to calculate P values for Age, BMI, SBP, DBP, Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides ApoB, Lipoprotein(a) and hs-CRP
  4. Chi square test was used to calculate P values for Gender, Smoking, Statins and Ezetimibe